Association Between Baseline Therapy and Flare Reduction in Mepolizumab-Treated Patients With Hypereosinophilic Syndrome

BACKGROUND: Current standard-of-care treatments for hypereosinophilic syndrome (HES) include oral corticosteroids (OCS) and immunosuppressive/cytotoxic (IS/CT) therapies. The anti-IL-5 monoclonal antibody mepolizumab has also recently been approved for patients with this disease. The objective of th...

Descripción completa

Detalles Bibliográficos
Autores principales: Reiter, Andreas, Lefevre, Guillaume, Cid, Maria C., Kwon, Namhee, Mavropolou, Eleni, Yancey, Steven W., Steinfeld, Jonathan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9044076/
https://www.ncbi.nlm.nih.gov/pubmed/35493455
http://dx.doi.org/10.3389/fimmu.2022.840974

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9044076/
https://www.ncbi.nlm.nih.gov/pubmed/35493455
http://dx.doi.org/10.3389/fimmu.2022.840974

Ejemplares similares